JP2011527334A - ヘテロ環式ｇｐｃｒ作動薬 - Google Patents

ヘテロ環式ｇｐｃｒ作動薬 Download PDF

Info

Publication number
JP2011527334A
JP2011527334A JP2011517248A JP2011517248A JP2011527334A JP 2011527334 A JP2011527334 A JP 2011527334A JP 2011517248 A JP2011517248 A JP 2011517248A JP 2011517248 A JP2011517248 A JP 2011517248A JP 2011527334 A JP2011527334 A JP 2011527334A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
alkyl
substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011517248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011527334A5 (https=
Inventor
リサ・サラ・バートラム
フィリップ・グレアム・クラーク
グレアム・ジョン・ドーソン
ピーター・ティモシー・フライ
マシュー・コリン・ソーア・ファイフ
ウィリアム・ガトレル
レバティ・ペルペチュア・ジーヴァラトナム
ジョン・カイリー
トーマス・マルティン・クルレ
マーティン・ジェイムズ・プロクター
クリステル・マリー・ラサミソン
コリン・ピーター・サムブルック−スミス
サイモン・アンドリュー・スウェイン
アラン・ジョン・ウィリアム・スチュアート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of JP2011527334A publication Critical patent/JP2011527334A/ja
Publication of JP2011527334A5 publication Critical patent/JP2011527334A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2011517248A 2008-07-10 2009-07-10 ヘテロ環式ｇｐｃｒ作動薬 Withdrawn JP2011527334A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0812648.4A GB0812648D0 (en) 2008-07-10 2008-07-10 Compounds
GB0812648.4 2008-07-10
PCT/GB2009/050830 WO2010004347A1 (en) 2008-07-10 2009-07-10 Heterocyclic gpcr agonists

Publications (2)

Publication Number Publication Date
JP2011527334A true JP2011527334A (ja) 2011-10-27
JP2011527334A5 JP2011527334A5 (https=) 2012-08-16

Family

ID=39722073

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011517248A Withdrawn JP2011527334A (ja) 2008-07-10 2009-07-10 ヘテロ環式ｇｐｃｒ作動薬

Country Status (6)

Country Link
US (1) US20110212939A1 (https=)
EP (1) EP2328867A1 (https=)
JP (1) JP2011527334A (https=)
CN (1) CN102131778A (https=)
GB (1) GB0812648D0 (https=)
WO (1) WO2010004347A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014534981A (ja) * 2011-11-15 2014-12-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｇｐｒ１１９アゴニストとして有用な置換シクロプロピル化合物
JP2017141224A (ja) * 2016-02-10 2017-08-17 大塚製薬株式会社 医薬組成物
JP2017525697A (ja) * 2014-08-28 2017-09-07 大塚製薬株式会社 二環式複素環化合物及びその結核治療用途
JP2017533213A (ja) * 2014-10-27 2017-11-09 ドン−ア エスティ カンパニー リミテッド Ｇｐｒ１１９作用活性を有する化合物、その製造方法およびこれを有効性分として含有する薬剤学的組成物
JP2022552655A (ja) * 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110230507A1 (en) * 2008-07-10 2011-09-22 Prosidion Limited Piperidine GPCR Agonists
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
WO2010114907A1 (en) 2009-03-31 2010-10-07 Vanderbilt University Sulfonyl-azetidin-3-yl-methylamine amide analogs as glyt1 inhibitors, methods for making same, and use of same in treating psychiatric disorders
AR077214A1 (es) 2009-06-24 2011-08-10 Neurocrine Biosciences Inc Heterociclos nitrogenados y composiciones farmaceuticas que los contienen
AU2010264720A1 (en) 2009-06-24 2011-12-08 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB2488360A (en) * 2011-02-25 2012-08-29 Prosidion Ltd Heterocyclic GPCR agonists
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
ITMI20100984A1 (it) * 2010-05-31 2011-12-01 Dipharma Francis Srl Procedimento per la preparazione di ossadiazoli
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012066077A1 (en) 2010-11-18 2012-05-24 Prosidion Limited 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
JP5935154B2 (ja) * 2011-03-14 2016-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ１１９モジュレーターとしてのｎ−シクロプロピル−ｎ−ピペリジニルベンズアミド
US8957062B2 (en) 2011-04-08 2015-02-17 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
JP6094578B2 (ja) 2011-06-09 2017-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン
CA2836487A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
EP2720544B1 (en) 2011-06-16 2016-12-21 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760855B1 (en) 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes
EP2771000B1 (en) 2011-10-24 2016-05-04 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
GB2498976A (en) * 2012-02-01 2013-08-07 Prosidion Ltd GPR119 agonists useful in the treatment of type II diabetes
HK1210825A1 (en) 2012-07-11 2016-05-06 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014184104A1 (en) 2013-05-17 2014-11-20 Boehringer Ingelheim International Gmbh Pyrrolidine derivatives, pharmaceutical compositions and uses thereof
CA2914525C (en) 2013-06-28 2021-07-27 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
KR101984281B1 (ko) * 2013-08-08 2019-05-31 동아에스티 주식회사 Gpr119 작용 활성을 갖는 신규 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
EP3068768B1 (en) 2013-11-15 2019-07-31 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016022742A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
WO2016068453A1 (en) * 2014-10-27 2016-05-06 Dong-A St Co., Ltd. Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
US10676458B2 (en) 2016-03-29 2020-06-09 Merch Sharp & Dohne Corp. Rahway Antidiabetic bicyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
US11225471B2 (en) 2017-11-16 2022-01-18 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
HUE071580T2 (hu) 2018-09-12 2025-09-28 Dong A St Co Ltd Hatóanyagként GPR119 ligandumot tartalmazó gyógyszerkészítmény nem alkoholos zsírmájbetegség megelõzésében vagy kezelésében történõ alkalmazásra
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
EP4320129A1 (en) * 2021-04-06 2024-02-14 Kallyope, Inc. Gpr119 agonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE188379T1 (de) * 1992-10-14 2000-01-15 Merck & Co Inc Fibrinogenrezeptor-antagonisten
US6100042A (en) * 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US6518423B1 (en) * 1996-08-09 2003-02-11 Eisai Co., Ltd. Benzopiperidine derivatives
US6221660B1 (en) * 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
AR043057A1 (es) * 2002-10-30 2005-07-13 Vertex Pharma Compuestos derivados de piridintiazoles como inhibidores de la quinasa rock y otras proteinas quinasa
CA2536253A1 (en) * 2003-08-20 2005-03-03 Vertex Pharmaceuticals Incorporated Aminofurazan compounds useful as protein kinase inhibitors
AR049333A1 (es) * 2004-04-02 2006-07-19 Vertex Pharma Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas.
WO2005105780A2 (en) * 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
MX2007016508A (es) * 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
PE20081659A1 (es) * 2007-01-04 2008-10-24 Prosidion Ltd Agonistas de gpcr
US20100048632A1 (en) * 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine GPCR Agonists
GB0700122D0 (en) * 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
PE20081849A1 (es) * 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
US20100048625A1 (en) * 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine gpcr agonists

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014534981A (ja) * 2011-11-15 2014-12-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｇｐｒ１１９アゴニストとして有用な置換シクロプロピル化合物
JP2017525697A (ja) * 2014-08-28 2017-09-07 大塚製薬株式会社 二環式複素環化合物及びその結核治療用途
JP2017533213A (ja) * 2014-10-27 2017-11-09 ドン−ア エスティ カンパニー リミテッド Ｇｐｒ１１９作用活性を有する化合物、その製造方法およびこれを有効性分として含有する薬剤学的組成物
US10428055B2 (en) 2014-10-27 2019-10-01 Dong-A St Co., Ltd. Substituted piperidines having GPR119 agonistic activity
JP2017141224A (ja) * 2016-02-10 2017-08-17 大塚製薬株式会社 医薬組成物
JP2022552655A (ja) * 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト

Also Published As

Publication number Publication date
WO2010004347A1 (en) 2010-01-14
EP2328867A1 (en) 2011-06-08
GB0812648D0 (en) 2008-08-20
CN102131778A (zh) 2011-07-20
US20110212939A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
JP2011527334A (ja) ヘテロ環式ｇｐｃｒ作動薬
JP4916452B2 (ja) Ｇｐｃｒ作動薬としてのピリジン、ピリミジン、およびピラジンの誘導体
JP5114395B2 (ja) Ｇｐｃｒアゴニスト
JP2011527335A (ja) ヘテロ環式ｇｐｃｒ作動薬
JP2011527331A (ja) ピペリジニルｇｐｃｒ作動薬
JP2011527332A (ja) ピペリジンｇｐｃｒ作動薬
JP4958560B2 (ja) Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
JP2011500659A (ja) アゼチジニルｇタンパク質共役受容体アゴニスト
JP2010514831A (ja) ピペリジンｇｐｃｒアゴニスト
JP2011527333A (ja) ピペリジニルｇｐｃｒ作動薬
JP2011500658A (ja) アゼチジニルｇタンパク質共役受容体アゴニスト
US20100022591A1 (en) Piperidine gpcr agonists
JP2009533410A (ja) Ｇタンパク質共役型受容体（ｇｐｒ１１９）アゴニストとしてのアゼチジン誘導体
JP2008545010A (ja) Ｇタンパク質共役受容体アゴニスト
JP2008545009A (ja) Ｇｐｃｒアゴニスト
JP2010514828A (ja) ピペリジンｇｐｃｒアゴニスト
JP2010514832A (ja) ピペリジンｇｐｃｒアゴニスト
JP2008545008A (ja) Ｇｐｃｒアゴニスト
JP2010514830A (ja) ピペリジンｇｐｃｒアゴニスト
JP2010539152A (ja) 代謝障害の治療のための化合物
HK1135704B (en) Piperidine gpcr agonists
HK1157329B (en) Piperidinyl gpcr agonists
HK1163680A (en) Piperidine gpcr agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120629

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130329